Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
5.00
-0.12 (-2.34%)
At close: Apr 28, 2026, 4:00 PM EDT
5.10
+0.10 (2.00%)
After-hours: Apr 28, 2026, 7:20 PM EDT
Opus Genetics Employees
As of December 31, 2025, Opus Genetics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 10 or 55.56% compared to the previous year.
Employees
28
Change (1Y)
10
Growth (1Y)
55.56%
Revenue / Employee
$507,000
Profits / Employee
-$1,771,107
Market Cap
357.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| Enanta Pharmaceuticals | 120 |
| Silence Therapeutics | 88 |
| Immuneering | 53 |
| X4 Pharmaceuticals | 45 |
| Surrozen | 44 |
| Compass Therapeutics | 39 |
| DiaMedica Therapeutics | 35 |
IRD News
- 1 day ago - Opus Genetics to Participate in Leading Medical Conferences in May 2026 - GlobeNewsWire
- 18 days ago - Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - GlobeNewsWire
- 22 days ago - Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - GlobeNewsWire
- 5 weeks ago - Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting - GlobeNewsWire
- 2 months ago - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire